Overactive bladder made ridiculously simple?

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 631-633

  Rosenberg, Matt T ^a  

^a Mid Michigan Health Centers Jackson   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

CLINICAL TRIAL; CYSTOSCOPY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HIP FRACTURE; HUMAN; NOCTURIA; OVERACTIVE BLADDER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SCREENING TEST; SYMPTOMATOLOGY; URGE INCONTINENCE; URINALYSIS; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; URODYNAMICS;

CLINICAL TRIALS; HUMANS; URINARY BLADDER, OVERACTIVE;

EID: 33744509615     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-11241.2006.00991.x     Document Type: Editorial

References (12)

1. Serels S. The Wet Patient: Understanding patients with overactive bladder and incontinence. Curr Med Res Opin 2004; 20: 791-801.
2. Coyne KS, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey. Value Health 2004; 7: 455-63.
3. Rosenberg MT, Dmochowski RR. Overactive bladder; evaluation and management in primary care. Cleve Clin J Med 2005; 72: 149-56.
4. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003; 78: 687-95.
5. Abrams P, Kaplan S et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction, J Urol 2006; 175: 99-1004.
6. Elinoff V, Bavendam T, Glasser D, Carlson, M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int J Clin Pract 2006; 60: 745-51.
7. Roberts R, Bavendam T, Glasser D, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient reported outcomes in overactive bladder: Results from the IMPACT trial. Int J Clin Pract 2006; 60: 752-8.
8. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
9. MacDiarmid S, Rosenberg M. Overactive bladder in women: Symptom impact and treatment expectations. Cur Med Res Opin 2005; 21: 1414-21.
10. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional wellbeing in six European countries. BJU Int 2005; 97: 96-100.
11. Darkov T, Fontes CL, Williamson TE. Cost associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005; 25: 511-9.
12. Hu TW, Wagner TH, Bentkover JD. Costs of urinary incontinence and overactive bladder in the United States: A comparative study. Urology 2004; 63: 461-5.